WEKO3
アイテム
Clinicopathological features and treatment strategy for triple-negative breast cancer
http://hdl.handle.net/2298/21162
http://hdl.handle.net/2298/21162dc27e197-b569-4ca1-b059-50ff0706db8c
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
Figure for TN paper_r.pdf (81.8 kB)
|
|
|
|
IJCO_15_4_341-351.pdf (157.3 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2011-09-01 | |||||
| タイトル | ||||||
| タイトル | Clinicopathological features and treatment strategy for triple-negative breast cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題 | Triple-negative breast cancer, Basal-like breast cancer, PARP1 inhibitors, Neoadjuvant chemotherapy, Adjuvant chemotherapy | |||||
| 資源タイプ | ||||||
| 資源タイプ | journal article | |||||
| 著者 |
山本, 豊
× 山本, 豊× Iwase, Hirotaka |
|||||
| 別言語の著者 |
山本, 豊
× 山本, 豊× 岩瀬, 弘敬 |
|||||
| 内容記述 | ||||||
| 内容記述 | Breast cancers are divided into at least 4 subtypes on the basis of gene expression profiles and expression of receptors (hormone receptors (HR) and HER2) as measured by immunohistochemistry. These subtypes have different prognoses and responses to treatments such as endocrine manipulation, anti-HER2 therapy, and chemotherapy. Triple-negative breast cancer (TNBC) is immunohistochemically defined as lacking estrogen and progesterone receptors and not overexpressing HER2. TNBC accounts for approximately 15% of breast cancer patients, and is more chemosensitive but has a worse prognosis than the HR-positive/HER2-negative phenotype. TNBC is a heterogeneous disease that does not offer specific targets in the same way as HR-positive and HER2- positive breast cancers, and is similar to basal-like breast cancer and BRCA1-related breast cancer. At present, the lack of highly effective therapeutic targets for TNBC leaves standard chemotherapy, for example the combination of anthracycline and taxane, as the only medical treatment, but this is insufficiently efficacious. Novel approaches for TNBC, for example DNA damaging agents, PARP-1 inhibitors, receptor tyrosin kinase inhibitors (TKIs), and antiangiogenesis agents, have been examined in clinical settings. Concerning therapeutic strategies for TNBC, it is most important to develop novel effective approaches for TNBC treatment and high-throughput predictive tools for standard chemotherapy and novel agents. | |||||
| 書誌情報 |
International Journal of Clinical Oncology 巻 15, 号 4, p. 341-351, 発行年 2010-08 |
|||||
| PubMed番号 | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 20632057 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 関連識別子 | 10.1007/s10147-010-0106-1 | |||||
| 権利 | ||||||
| 権利情報 | ©Japan Society of Clinical Oncology 2010 | |||||
| 情報源(ISSN) | ||||||
| 関連名称 | 13419625 | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| 形態 | ||||||
| 157284 bytes | ||||||
| 形態 | ||||||
| 81782 bytes | ||||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 日本十進分類法 | ||||||
| 主題Scheme | NDC | |||||
| 主題 | 495.4 | |||||
| 出版者 | ||||||
| 出版者 | 日本癌治療学会 | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 論文(Article) | |||||
| 資源タイプ・ローカル | ||||||
| 雑誌掲載論文 | ||||||
| 資源タイプ・NII | ||||||
| Journal Article | ||||||
| 資源タイプ・DCMI | ||||||
| text | ||||||
| 資源タイプ・ローカル表示コード | ||||||
| 01 | ||||||
| URL | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | http://www.springerlink.com/content/156637j621817465/ | |||||
| コメント | ||||||
| The original publication is available at www.springerlink.com | ||||||
